Innate Pharma Stock Quote IPHA - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

2.16

Bid

2.06

Ask

3.00

Volume

2,083

2.16 Day's Range 2.25

0.00 52 Week Range 0.00

Market Cap

172.975M

Previous Close

2.15

Open

2.25

Last Trade

2.24

Last Trade Time

Financial Volume

$ 4,639

VWAP

2.227

Average Volume (3m)

Shares Outstanding

80,453,282

Dividend Yield

PE Ratio

-22.74

Earnings Per Share (EPS)

-0.09

Revenue

61.64M

Net Profit

-7.57M

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therap... Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.innate-pharma.com

Headquarters

Marseille, Bouches-du-rhone, Fra

Founded

1970

Innate Pharma SA is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IPHA. The last closing price for Innate Pharma was $2.15. Over the last year, Innate Pharma shares have traded in a share price range of $ 0.00 to $ 0.00.

Innate Pharma currently has 80,453,282 shares outstanding. The market capitalization of Innate Pharma is $172.97 million. Innate Pharma has a price to earnings ratio (PE ratio) of -22.74.

Nouveau nombre d’actions et de droits de vote d’Innate Pharma au 10 juin 2024

Regulatory News: Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate Pharma SA (Euronext Paris : IPH...

Innate Pharma partage de nouveaux résultats concernant l’essai de Phase 1/2 mené par Sanofi évaluant le NK cell engager SAR443579/IPH6101 dans divers cancers du sang

SAR443579/IPH6101, le candidat-médicament le plus avancé de la plateforme ANKET®, est un NK Cell Engager first-in-class engageant les récepteurs NKp46/CD16 et ciblant CD123, issu d’un accord de...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MIRAMIRA Pharmaceuticals Inc	$ 5.01 (627.35%)	151.42M
CMAXCareMax Inc	$ 5.7101 (261.40%)	100.56M
NUKKNukkleus Inc	$ 0.5415 (69.22%)	24.87M
SNOASonoma Pharmaceuticals Inc	$ 0.423 (37.34%)	4.57M
LPSNLivePerson Inc	$ 1.2999 (31.30%)	8.57M
CGBSCrown LNG Holdings Ltd	$ 0.9902 (-29.77%)	3.29M
LGCBLinkage Global Inc	$ 3.7833 (-27.45%)	166.7k
SPECSpectaire Holdings Inc	$ 0.395 (-24.76%)	1.78M
GSUNGolden Sun Health Technology Group Ltd	$ 5.07 (-24.55%)	155.37k
SLNASelina Hospitality PLC	$ 0.0364 (-23.04%)	75.77M
NVDANVIDIA Corporation	$ 123.45 (4.68%)	221.22M
SQQQProShares UltraPro Short QQQ	$ 8.08 (-4.49%)	176.65M
MIRAMIRA Pharmaceuticals Inc	$ 5.01 (627.35%)	151.42M
SERVServe Robotics Inc	$ 8.7192 (15.49%)	148.59M
NCPLNetcapital Inc	$ 0.1105 (6.25%)	121.97M